Establishment of a Multi-omics Prediction Model for Early Triple-negative Breast Cancer Based on UPGRADE-TNBC Study
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Based on the UPGRADE-TNBC study, a high-quality TNBC sample repository was established. By integrating multi-source data-including clinical information, radiomics, pathological images, and molecular sequencing-and innovatively incorporating a meta-learning strategy, a treatment response prediction model based on multimodal small-sample learning was developed. This approach aims to optimize drug combinations and precisely identify patient subgroups likely to benefit from treatment, thereby providing a new paradigm for personalized therapy in early-stage TNBC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Uczestnicy badania UPGRADE-TNBC
✗ Disqualifies
- •Osoby spoza grupy badanej UPGRADE-TNBC
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- August 19, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China
Trial contact
Xue Wang
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/20/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.